TABLE 1.
Patient characteristics at time of advanced disease diagnosis for the total group of patients systemically treated for HR+/HER2− ABC, and for the cohorts of patients eligible for CDK4/6 inhibitors since the reimbursement date (August 2017) and diagnosed before and beyond this date
| Patient characteristics | Total group, ABC diagnosis 2009‐2018 (n = 1407) | ABC diagnosis 2009‐July 2017 (n = 417) | ABC diagnosis August 2017‐December 2018 (n = 214) |
|---|---|---|---|
| Sex, female | 1395 (99) | 413 (99) | 213 (100) |
| Age (y), median (range) | 66.1 (29‐98) | 66.2 (32‐98) | 66.7 (29‐91) |
| WHO performance status a | |||
| 0‐2 | 1051 (95) | 339 (97) | 183 (92) |
| 3‐4 | 56 (5) | 9 (3) | 16 (8) |
| Unknown | 300 | 66 | 12 |
| Comorbidities | |||
| Any | 806 (57) | 235 (56) | 125 (58) |
| Pulmonary | 137 (10) | 38 (9) | 29 (14) |
| Cardiovascular | 547 (39) | 154 (37) | 81 (38) |
| Cerebrovascular | 105 (8) | 33 (8) | 21 (10) |
| Other malignancy | 119 (9) | 34 (8) | 17 (8) |
| Histology | |||
| Ductal carcinoma | 1012 (75) | 301 (75) | 157 (76) |
| Lobular carcinoma | 318 (23) | 93 (23) | 45 (22) |
| Other | 27 (2) | 10 (2) | 5 (2) |
| Unknown | 50 | 13 | 7 |
| Hormone receptor status | |||
| ER positive | 1402 (100) | 417 (100) | 214 (100) |
| PR positive | 870 (62) | 282 (68) | 125 (58) |
| Initial metastatic sites | |||
| Nonvisceral | 1215 (86) | 365 (88) | 185 (86) |
| Bone only | 457 (33) | 157 (38) | 72 (34) |
| Soft tissue | 481 (34) | 150 (36) | 71 (33) |
| Visceral b | 739 (53) | 174 (42) | 110 (51) |
| Lung | 297 (21) | 74 (18) | 36 (17) |
| Liver | 362 (26) | 67 (16) | 58 (27) |
| Pleura | 210 (15) | 56 (13) | 41 (19) |
| Central nervous system | 52 (4) | 13 (3) | 5 (2) |
| Initial number of metastatic sites | |||
| 1 | 652 (46) | 221 (53) | 104 (48) |
| 2 | 410 (29) | 113 (27) | 68 (32) |
| ≥3 | 345 (25) | 83 (20) | 42 (20) |
| Metastatic‐free interval c | |||
| De novo (<3 mo) | 355 (25) | 116 (28) | 51 (24) |
| 3‐23 mo | 118 (8) | 22 (5) | 18 (8) |
| ≥24 mo | 934 (66) | 279 (67) | 145 (68) |
| Prior (neo‐)adjuvant therapy d | |||
| Endocrine therapy | 741 (70) | 184 (61) | 79 (48) |
| Chemotherapy | 502 (47) | 127 (42) | 117 (72) |
Note: Data given as number (%) unless otherwise indicated.
Abbreviations: ABC, advanced breast cancer; CDK4/6, cyclin‐dependent kinase 4/6; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PR, progesterone receptor; WHO, World Health Organization.
WHO performance status is measured on a 5‐point scale, WHO 0 indicates no restrictions in activity and higher numbers indicate increasing inability.
Visceral metastases: liver, lung, pleura, peritoneal and/or gastrointestinal metastases.
Metastatic‐free interval is defined as interval between date of breast cancer and date of ABC diagnosis.
Among patients with recurrent metastases (excluding patients with de novo ABC).